Milton High School Senior  Shreya Ramesh  Achieves Global Excellence in Scientific Research

ATLANTA–( BUSINESS WIRE )–Shreya Ramesh, a Milton High School senior, from Milton, Georgia, and local winner of the Georgia BioGENEius Challenge, has taken the top prize at the fiercely competitive International BioGENEius Challenge. Shreya’s innovative work on voice recognition data and Amyotrophic Lateral Sclerosis (ALS) stood out among her fellow finalists.

“We just couldn’t be more ecstatic—for Shreya as well as for the future of all biotech innovation,” said Georgia Bio President and CEO Maria Thacker. “We knew how talented she was when we saw her work, but the fact that our local winner’s unbelievably sophisticated research won the top prize at this advanced level shows you just what we can do in biotech here in Georgia, not to mention how brilliant and innovative Georgia students are.”

Organized by the Biotechnology Institute, the annual competition brings together young innovators from across North America and Germany to compete before an accomplished panel of established biotechnology researchers and academics. The winner walks away with the recognition, advisement, and support of some of the world’s best biotech innovators as well $7,500 in prize money.

Shreya’s research topic focused on the problem of Amyotrophic Lateral Sclerosis (ALS) patients, many of whom rely on Automatic Speech Recognition (ASR) tools such as Google Voice, with voice characteristics that can unfortunately be unreadable to ARS programs. As a result of the condition, the voices of ALS patients can be slow and high pitched, making ARS software interaction problematic. Shreya’s solution was to create a novel voice compensation algorithm that converted an ALS patient’s unique vocal texture into one more easily recognized by the programs.

“Winning the BioGENEius Challenge feels absolutely amazing,” said Shreya Ramesh. “It’s great to know that my project has the potential to change lives and that I’ll have a supportive platform to help me do that. The competition was the  best  experience—I’ve met so many students who are just as passionate as I am about using biotech to change the world!”

Judges of the 2020 International BioGENEius Challenge included BioEd Institute Board Member and past Chair, Jamie Graham, partner at Kilpatrick Townsend & Stockton, to whom Georgia Bio and the Georgia BioEd Institute offer a special thanks.

About the Biotechnology Institute

The Biotechnology Institute is an independent, national nonprofit organization dedicated to education about the present and future impact of biotechnology. Its mission is to engage, excite and educate the public, particularly students and teachers, about biotechnology and its immense potential for solving human health, food and environmental problems. For more information, visit  www.biotechinstitute.org.

About the Georgia BioEd Institute 

The Georgia BioEd Institute is a division of Georgia Bio, a 501(c)(3) nonprofit organization serving the state’s life science industry. The Institute’s mission is to strengthen Georgia’s life sciences workforce pipeline through classroom-to-career initiatives that align with industry needs. Learn more at  www.georgiabioed.org  |  www.gabio.org.

Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

By Sheran Brown • February 21, 2025
Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

Bipartisan PBM Reform Back in Focus as House Committee Plans Hearing

By Sheran Brown • February 20, 2025
A renewed push for prescription drug cost reform is gaining momentum in Congress, with the House Energy and Commerce Committee's health subcommittee planning a hearing on pharmacy benefit manager (PBM) reform for late February. The hearing, to be led by Rep. Buddy Carter (R-Ga.), signals a revival of bipartisan efforts to regulate these pharmaceutical intermediaries. PBMs, which negotiate drug prices for insurers and employers, have become a focal point in the broader discussion of healthcare costs. A previous bipartisan agreement to regulate these entities was crafted by Carter and Rep. Diana DeGette (D-Colo.) in the last Congress, though it ultimately stalled when the larger spending bill it was attached to faced opposition. The reform efforts enjoy broad support from both parties and the president, making it one of the few areas with potential for bipartisan cooperation. However, new complications have emerged as Republicans consider using PBM regulations to generate savings for their broader policy agenda, potentially requiring up to $880 billion in cost reductions. The path forward remains uncertain, with ongoing debates about whether such reforms would qualify for budget reconciliation and whether using PBM regulations as a funding mechanism could derail bipartisan cooperation. Meanwhile, stakeholders continue to disagree on the impact of additional PBM regulation, with pharmaceutical companies arguing that PBMs inflate drug costs while PBMs contend that new regulations would increase prices.

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

By Sheran Brown • February 20, 2025
The Council of State Biotechnology Associations (CSBA) has issued a strong warning about proposed cuts to National Institutes of Health (NIH) funding, emphasizing the critical role these grants play in America's biotech innovation ecosystem. The statement, below , comes amid concerns over recent guidance that would reduce NIH funding to key research institutions. ----------------------- “Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return on investment. As the associations representing the bioscience industry across the nation, the Council on State Biotechnology Associations (CSBA) is concerned by recent guidance that would cut funding provided by the NIH to universities, hospitals, and other institutions that perform critical early-stage research. NIH grant funds are a critical component of our innovation ecosystem. Grants for basic research are the spark that leads to university-driven discoveries, with public-private partnerships and tech transfers that bridge early-stage research to industry-sponsored drug development and ultimately to FDA approved medical advances for hundreds of diseases. While the administration looks for greater efficiency in the use of taxpayer dollars, it cannot be overstated - once scientific innovation moves abroad, it may never return. In the race for scientific innovation around the world, as our adversaries continue to increase government investments in research, we encourage President Trump to follow suit and ensure that we maintain our global leadership in an industry that was created and thrives across the US.”
MORE POSTS
Share by: